Inventor · disambiguated record
Kinfe Ken Redda
Also filed as: REDDA KINFE · REDDA KINFE KEN
9 granted patents·1 pending application·16 citations·filing 1976–2022
80Inventor score
Files withFLORIDA A&M UNIV3CANADIAN PATENTS DEV2REDDA KINFE2REDDA KINFE KEN2FLORIDA A & M UNIVERSITY1
Top patents by PatentIndex Score
10 records- 0178US8889713B1N-substituted tetrahydroisoquinoline benzamides/benzene sulfonamides as anti-cancer agentsFLORIDA A & M UNIVERSITY·Filed 2013·Granted Nov 18, 2014·3 cites·15 claims
- 0272US4088653ATetrahydropyridyl derivativesCANADIAN PATENTS DEV·Filed 1976·Granted May 9, 1978·8 cites·19 claims
- 0364US8546426B2N-aminotetrahydroisoquinolines as anti-cancer agentsREDDA KINFE KEN·Filed 2011·Granted Oct 1, 2013·1 cites·19 claims
- 0459US10646479B2Use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetrahydropyridine as a treatment for cancerFLORIDA A&M UNIV·Filed 2019·Granted May 12, 2020·0 cites·9 claims
- 0558US11839609B1Substituted tetrahydroisoquinolines as anti-mitotic drug in triple negative breast cancerFLORIDA A&M UNIV·Filed 2022·Granted Dec 12, 2023·0 cites·16 claims
- 0652US4338445AN-(Carbonylamino)-tetrahydropyridyl derivativesCANADIAN PATENTS DEV·Filed 1980·Granted Jul 6, 1982·4 cites·9 claims
- 0739US8476303B2N-aminopyrrolylmethyltetrahydropyridines as anti-cancer agentsREDDA KINFE KEN·Filed 2011·Granted Jul 2, 2013·0 cites·15 claims
- 0836US10730840B2Substituted tetrahydroisoquinoline ethylbenzamide anti-cancer agentsFLORIDA A&M UNIV·Filed 2018·Granted Aug 4, 2020·0 cites·23 claims
- 0936US8314143B2Synthetic flavonoids and pharmaceutical compositions and therapeutic methods of treatment of HIV infection and other pathologiesREDDA KINFE·Filed 2007·Granted Nov 20, 2012·0 cites·33 claims
- 1031US2009312407A1Synthetic Flavonoids and Pharmaceutical Compositions and Therapeutic Methods of Treatment of Cancer and other PathologiesREDDA KINFE·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kinfe Ken Redda files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →